Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Stephen Freedland MD

Stephen J. Freedland MD

Professor, Division of Urology, Department of Surgery; Director, Center for Integrated Research in Cancer and Lifestyle; Co-Director, Cancer Genetics and Prevention Program; Cedars-Sinai Medical Center, Los Angeles, California; and Staff Physician, Section of Urology, Durham VA Medical Center, Durham, North Carolina

Dr. Stephen Freedland is now Director, Center for Integrated Research in Cancer and Lifestyle, Co-Director, Cancer Genetics and Prevention Program, Associate Director, Faculty Development, Cedars-Sinai, Los Angeles, CA. He was a Urologist within the Duke Prostate Center at Duke University.  He is an Associate Professor of Surgery (Urology) and Pathology.  He also holds an appointment at the Durham VA Hospital.  He is Editor-in-Chief of Prostate Cancer and Prostatic Diseases and sits on the editorial board of numerous international journals in Urology. He specializes in the diagnosis, treatment, and long-term management of prostate cancer patients. He has extensive research interests in risk stratification, the role of obesity and nutrition in prostate cancer, and health disparities for prostate cancer. He completed his undergraduate at UCLA and then medical school at UC Davis.  Following this, he completed his residency in Urology at UCLA and a urological oncology fellowship at Johns Hopkins.  He currently runs an active research program with funding from the National Cancer Institute and the Department of Defense.